All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Recovery comparison

BPC-157 Arginate vs Cartalax

An educational, source-based comparison of BPC-157 Arginate and Cartalax — how each peptide works, what it's researched for, and what to know before going deeper.

Tissue Repair · Gastrointestinal
BPC-157 Arginate

Stabilized salt form of BPC-157 with enhanced stability.

Mechanism

An arginate salt formulation of BPC-157 designed to improve stability and shelf-life. Research suggests the same angiogenic, anti-inflammatory, and tissue-repair mechanisms as standard BPC-157, with potentially improved bioavailability.

Research areas
  • Tendon and ligament healing
  • Gastric ulcer protection
  • Neuroprotection and nerve repair
  • Systemic anti-inflammatory effects
Considerations
  • Same cautions as standard BPC-157: preclinical data, not FDA-approved.
  • Quality of compounded formulations varies widely.
Full BPC-157 Arginate profile →
Musculoskeletal · Bioregulator
Cartalax

Tripeptide bioregulator researched for cartilage and joint support.

Mechanism

A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.

Research areas
  • Osteoarthritis and cartilage repair
  • Joint mobility in aging
  • Tendon and ligament integrity
Considerations
  • Preclinical and Russian clinical data only.
  • Not FDA-approved.
Full Cartalax profile →

BPC-157 Arginate vs Cartalax — Key differences

  • Class: BPC-157 Arginate is classified as Tissue Repair · Gastrointestinal, while Cartalax is Musculoskeletal · Bioregulator.
  • Primary research focus: BPC-157 Arginatetendon and ligament healing; Cartalaxosteoarthritis and cartilage repair.
  • Tag: Recovery vs Joint · Bioregulator.

Related comparisons